ALung Technologies develops the Hemolung Respiratory Assist System (RAS), a minimally invasive artificial lung that removes carbon dioxide independently of the lungs using a process called Respiratory Dialysis®. The company focuses on low‑flow extracorporeal carbon dioxide removal (ECCO2R) to treat patients with acute respiratory failure. The Hemolung RAS has been used to treat hundreds of patients outside the United States since 2013 and received FDA Expedited Access Pathway designation in 2015. ALung plans to use new funding to support a U.S.‑based pivotal clinical trial aimed at FDA approval and broader availability in the United States. The company is privately held and headquartered in Pittsburgh; it was founded in 1997. The recent financing strengthens clinical and commercialization plans while adding strategic partners to its board and advisory ranks. ALung Technologies is a privately held Pittsburgh-based developer and manufacturer of low-flow extracorporeal carbon dioxide removal (ECCO2R) technologies, notably the Hemolung RAS which uses a Respiratory Dialysis® process. The Hemolung RAS is positioned as a dialysis-like alternative or supplement to mechanical ventilation for acute respiratory failure, with applications in ARDS and COPD. The company reports CE mark clearance in 2013, global clinical adoption at leading centers, and that hundreds of patients have been treated with the technology. ALung is pursuing a share of the estimated $6 billion acute respiratory failure market. The company plans to use recent financing to support continued commercialization and to complete work required to obtain IDE approval for a U.S.-based clinical trial following its Expedited Access Pathway (EAP) designation. ALung was founded in 1997 and is backed by individual investors and venture firms named in its filings. ALung Technologies develops and manufactures the Hemolung Respiratory Assist System (RAS), a low‑flow, minimally invasive extracorporeal carbon dioxide removal (ECCO2R) device. The Hemolung provides Respiratory Dialysis® as an alternative or supplement to mechanical ventilation with indications including acute exacerbation of COPD and ARDS. The device was tested at 43 hospitals in 13 countries and following a successful clinical trial in Germany received regulatory clearances in Europe and Canada. ALung initiated a controlled launch in mid‑2013 and has accelerated commercial roll‑out in Germany, the UK, France, Canada, and Australia. The Hemolung RAS is currently approved in 29 countries across Europe, the Middle East, and Asia‑Pacific. The company says it will use new financing to accelerate global commercialization of the technology. ALung Technologies develops extracorporeal respiratory assist devices, principally the Hemolung Respiratory Assist System (RAS), a dialysis-like extracorporeal carbon dioxide removal (ECCO2R) system. The Hemolung RAS provides Respiratory Dialysis® as a simple, minimally invasive alternative or supplement to mechanical ventilation and has indications for ARDS and acute exacerbation of COPD. The device is approved for sale in Europe and Canada, and ALung has established direct commercial operations in Germany, France, and the United Kingdom while entering additional markets through distribution partners. The company intends to use new capital to support global commercialization and to further develop next-generation products and platform technologies for less-invasive extracorporeal lung support. To date ALung has raised $56 million in equity capital, and the recent financing will primarily support the global launch of the Hemolung RAS. ALung's lead product, HemoLung, is an extracorporeal artificial lung that removes carbon dioxide from blood while infusing oxygen via a catheter into the femoral or jugular vein. The device is intended for patients with acute respiratory failure to help them avoid mechanical ventilation. Four months after receiving CE Mark approval, ALung is commercializing HemoLung in Germany, France, the UK and Canada and plans sales in Canada and Australia. The company has set up 10 reference centers, is hiring clinical specialists and support staff, and is seeking distributors in Europe, Canada and Australia. ALung estimates a patient population of about 900,000 and a market opportunity of roughly $4.6 billion. The company was started in 1997 by Dr. Brack Hattler and Bill Federspiel.

Total raised

$116M

Funding rounds

10

Latest round

Series C

Latest activity

Apr 2017